Camizestrant Explained

Legal Status:	Investigational
Cas Number:	2222844-89-3
Pubchem:	134453496
Iuphar Ligand:	12716
Drugbank:	DB19218
Chemspiderid:	103820855
Unii:	JUP57A8EPZ
Kegg:	D12049
Chembl:	4650365
Synonyms:	AZD9833
Iupac Name:	N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine
C:	24
H:	28
F:	4
N:	6
Smiles:	C[C@@H]1CC2=C(C=CC3=C2C=NN3)[C@H](N1CC(F)(F)F)C4=NC=C(C=C4)NC5CN(C5)CCCF
Stdinchi:	1S/C24H28F4N6/c1-15-9-19-18(4-6-21-20(19)11-30-32-21)23(34(15)14-24(26,27)28)22-5-3-16(10-29-22)31-17-12-33(13-17)8-2-7-25/h3-6,10-11,15,17,23,31H,2,7-9,12-14H2,1H3,(H,30,32)/t15-,23+/m1/s1
Stdinchikey:	WDHOIABIERMLGY-CMJOXMDJSA-N

Camizestrant is an investigational new drug that is being evaluated to treat breast cancer.^[1] It is an estrogen receptor alpha antagonist and a selective estrogen receptor degrader (SERD).^[2]

Notes and References

Web site: Camizestrant - AstraZeneca . AdisInsight . Springer Nature Switzerland AG .
Scott JS, Moss TA, Balazs A, Barlaam B, Breed J, Carbajo RJ, Chiarparin E, Davey PR, Delpuech O, Fawell S, Fisher DI, Gagrica S, Gangl ET, Grebe T, Greenwood RD, Hande S, Hatoum-Mokdad H, Herlihy K, Hughes S, Hunt TA, Huynh H, Janbon SL, Johnson T, Kavanagh S, Klinowska T, Lawson M, Lister AS, Marden S, McGinnity DF, Morrow CJ, Nissink JW, O'Donovan DH, Peng B, Polanski R, Stead DS, Stokes S, Thakur K, Throner SR, Tucker MJ, Varnes J, Wang H, Wilson DM, Wu D, Wu Y, Yang B, Yang W . Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist . Journal of Medicinal Chemistry . 63 . 23 . 14530–14559 . December 2020 . 32910656 . 10.1021/acs.jmedchem.0c01163 .